Intratumoral injection of PKR shRNA expressing plasmid inhibits B16-F10 melanoma growth Corrigendum in /10.3892/or.2018.6646

André,Nayara  Delgado; Silva,Viviane  Aline Oliveira; Watanabe,Maria  Angelica Ehara; De Lucca,Fernando   Luiz

doi:10.3892/or.2014.3410

Intratumoral injection of PKR shRNA expressing plasmid inhibits B16-F10 melanoma growth

Corrigendum in: /10.3892/or.2018.6646

Authors:
- Nayara Delgado André
- Viviane Aline Oliveira Silva
- Maria Angelica Ehara Watanabe
- Fernando Luiz De Lucca
View Affiliations

Affiliations: Federal University of São João del-Rei, 35501296 Divinópolis, MG, Brazil, Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, 14049-900 Ribeirão Preto, SP, Brazil, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, 86057-970 Londrina, PR, Brazil
Published online on: August 18, 2014 https://doi.org/10.3892/or.2014.3410
Pages: 2267-2273

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The RNA-dependent protein kinase (PKR) is a serine/threonine kinase that is involved in the regulation of important cell processes such as apoptosis, signal transduction, cell proliferation and differentiation. However, the role played by PKR in cancer remains controversial. RNA interference (RNAi) has currently become an important technique in understanding gene function. Previously, we showed that PKR shRNA downregulates PKR expression in B16-F10 melanoma cells and reduces the metastatic potential of these tumor cells. In the present study, we examined the effect of the intratumoral injection of PKR shRNA‑expressing plasmid on the growth of B16-F10 melanoma in mice. The results showed that this treatment significantly reduced tumor growth. Thus, these findings suggested that PKR acts as a tumor suppressor, a finding that is consistent with our previous study on the experimental model of metastasis. Moreover, the results suggested that this effect may be mediated by the transcription factor NF-κB. The present study confirmed the hypothesis that the direct administration of RNAi-based therapeutics in the target tumor is a promising approach for overcoming the obstacles of systemic delivery. The results also suggested that the intratumoral injection of PKR shRNA‑expressing vector is a novel therapeutic approach for human solid tumors such as cutaneous melanoma and breast cancer, since PKR is overexpressed in these tumors.

View Figures

View References

1	Clemens MJ and Elia A: The double-stranded RNA-dependent protein kinase PKR: Structure and function. J Interferon Cytokine Res. 17:503–524. 1997. View Article : Google Scholar : PubMed/NCBI
2	García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C and Esteban M: Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol. 70:1032–1060. 2006.PubMed/NCBI
3	Murad JM, de Souza LR and De Lucca FL: PKR activation by a non-coding RNA expressed in lymphocytes of mice bearing B16 melanoma. Blood Cells Mol Dis. 37:128–133. 2006. View Article : Google Scholar : PubMed/NCBI
4	Watanabe MAE, Souza LR, Murad JM and De Lucca FL: Activation of the RNA dependent protein kinase (PKR) of lymphocytes by regulatory RNAs: implications for immunomodulation in HIV infection. Curr HIV Res. 3:329–337. 2005. View Article : Google Scholar : PubMed/NCBI
5	Patel RC and Sen GC: PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17:4379–4390. 1998. View Article : Google Scholar : PubMed/NCBI
6	Singh M and Patel RC: Increased interaction between PACT molecules in response to stress signals is required for PKR activation. J Cell Biochem. 113:2754–2764. 2012. View Article : Google Scholar : PubMed/NCBI
7	Williams BR: PKR: a sentinel kinase for cellular stress. Oncogene. 18:6112–6120. 1999. View Article : Google Scholar : PubMed/NCBI
8	Marchal JA, Lopez GJ, Peran M, Comino A, Delgado JR, García-García JA, Conde V, Aranda FM, Rivas C, Esteban M and Garcia MA: The impact of PKR activation: from neurodeggeneration to cancer. FASEB J. 28:1965–1974. 2014. View Article : Google Scholar : PubMed/NCBI
9	Murad JM, Tone LG, Souza LR and De Lucca FL: A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis. 34:1–5. 2005. View Article : Google Scholar : PubMed/NCBI
10	Delgado-André N and De Lucca FL: Knockdown of PKR expression by RNAi reduces pulmonary metastatic potential of B16-F10 melanoma cells in mice: possible role of NF-kappaB. Cancer Lett. 258:118–125. 2007.PubMed/NCBI
11	Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu DQ: Downregulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res. 11:6333–6341. 2005. View Article : Google Scholar : PubMed/NCBI
12	Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK and Tang T: Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
13	Díaz MR and Vivas-Mejia PE: Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes. Pharmaceuticals. 6:1361–1380. 2013.PubMed/NCBI
14	Li CH, Parker A, Menocal E, Xiang S, Borodyansky L and Fruehauf JH: Delivery of RNA interference. Cell Cycle. 5:2103–2109. 2006. View Article : Google Scholar
15	Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H and Harashima H: Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther. 21:1195–1203. 2013. View Article : Google Scholar : PubMed/NCBI
16	Deharvengt SJ, Gunn JR, Pickett SB and Korc M: Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther. 17:325–333. 2010. View Article : Google Scholar : PubMed/NCBI
17	Fujita Y, Takeshita F, Kuwano K and Ochiya T: RNAi therapeutic platforms for lung diseases. Pharmaceuticals. 6:223–250. 2013. View Article : Google Scholar : PubMed/NCBI
18	Nikitenko NA and Prassolov VS: Non-viral delivery and therapeutic application of small interfering RNAs. Acta Naturae. 5:35–53. 2013.PubMed/NCBI
19	Das J, Das S, Paul A, Samadder A, Bhattacharyya SS and Khuda-Bukhsh AR: Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicol Lett. 225:454–466. 2014. View Article : Google Scholar : PubMed/NCBI
20	Paddison PJ, Caudy AA, Bernstein E, Hannon G and Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:948–958. 2002. View Article : Google Scholar : PubMed/NCBI
21	Kumar A, Haque J, Lacoste J, Hiscott J and Williams BR: Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA. 91:6288–6292. 1994. View Article : Google Scholar : PubMed/NCBI
22	Gil J, Alcamí J and Esteban M: Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene. 19:1369–1378. 2000. View Article : Google Scholar : PubMed/NCBI
23	Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P and Ghosh S: I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell. 80:573–582. 1995. View Article : Google Scholar : PubMed/NCBI
24	Lindgren H, Olsson AR, Pero RW and Leanderson T: Differential usage of IkappaBalpha and IkappaBbeta in regulation of apoptosis versus gene expression. Biochem Biophys Res Commun. 301:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
25	Haneji T, Hirashima K, Teramachi J and Morimoto H: Okadaic acid activates the PKR pathway and induces apoptosis through PKR stimulation in MG63 osteoblast-like cells. Int J Oncol. 42:1904–1910. 2013.PubMed/NCBI
26	De Lucca FL, Serrano SV, Souza LR and Watanabe MA: Activation of RNA-dependent protein kinase and nuclear factor-kB by regulatory RNA from lipopolysaccharide-stimulated macrophages: implications for cytokine production. Eur J Pharmacol. 450:85–89. 2002.PubMed/NCBI
27	Watanabe MA, Rodrigues Souza L, Murad JM and De Lucca FL: Antitumor activity induced by regulatory RNA: possible role of RNA-dependent protein kinase and nuclear factor-kappa B. Eur J Pharmacol. 465:205–210. 2003. View Article : Google Scholar : PubMed/NCBI